UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 6 28, 2026

Castle Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38984

77-0701774

(state or other jurisdictionof incorporation)

(CommissionFile Number)

(I.R.S. EmployerIdentification No.)

(State or other jurisdictionof incorporation)

(CommissionFile Number)

(IRS EmployerIdentification No.)

1500 W. Parkwood Ave, Suite 400

Friendswood, Texas

77546

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (866) 788-9007

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

CSTL

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–-2 of the Securities Exchange Act of 1934 (§ 240.12b–-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.~~02 Results~~ 07 Submission of ~~Operations and Financial Condition~~ Matters to a Vote of Security Holders.

On May 628, 2026, Castle Biosciences, Inc. (the “Company”) ~~issued~~held aits ~~press~~2026 ~~release~~annual ~~announcing~~meeting ~~its~~of ~~financial~~stockholders ~~results~~(the ~~for~~“Annual ~~the~~Meeting”). ~~first~~At ~~quarter~~the ~~ended~~Annual ~~March 31~~Meeting, ~~2026.~~the ACompany’s ~~copy~~stockholders ofvoted on the ~~press~~following ~~release~~matters isand ~~attached~~cast ~~hereto~~their votes as ~~Exhibit~~set ~~99.1~~forth ~~and incorporated herein by reference.~~below:

~~The~~Proposal ~~information contained or incorporated in this Current Report on Form 8-K, including Exhibit 99.~~1,. ~~shall~~Election ~~not be deemed “filed” for purposes~~ of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.Directors

~~Item~~The ~~7.01 Regulation~~Company’s FDstockholders ~~Disclosure~~elected the three individuals listed below as Class I Directors, each to serve until the Company’s 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The final voting results are as follows:

On May 6, 2026, the Company made available the slide presentation attached hereto as Exhibit 99.2. Information from this slide presentation may also be used by the management of the Company in future meetings regarding the Company.


	For	Withhold	Broker Non-Votes
Ellen Goldberg	15,455,265	7,118,166	2,415,788
Miles D. Harrison	15,607,369	6,966,062	2,415,788
Tiffany P. Olson	14,380,655	8,192,776	2,415,788

~~The~~Proposal ~~information contained or incorporated in this Item 7~~2.01 ofRatification ~~this Current Report on Form 8-K, including Exhibit 99.2, shall not be deemed “filed” for purposes~~ of ~~Section 18 of~~ the ~~Exchange~~Selection ~~Act or otherwise subject to the liabilities~~ of ~~that~~Independent ~~section,~~Registered ~~nor~~Public ~~shall~~Accounting it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.Firm

~~Item~~The ~~9.01 Financial~~Company’s ~~Statements~~stockholders ~~and~~ratified ~~Exhibits~~the selection of KPMG LLP by the Audit Committee of the Company’s Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:

Exhibit
For	Against	Abstain
Number	Description
24,531,366	445,666	12,187
99.1	Press release issued May 6, 2026.
99.2	Slide presentation.
104	Inline XBRL for the cover page of this Current Report on Form 8-K.

Proposal 3. Approval of the Compensation of the Company’s Named Executive Officers

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 8, 2026 (the “Proxy Statement”). The final voting results are as follows:


For	Against	Abstain	Broker Non-Votes
21,280,180	1,281,394	11,857	2,415,788

Proposal 4. Approval of the Company’s Non-Employee Director Compensation Policy

The Company’s stockholders approved the Company’s non-employee director compensation policy as described in the Proxy Statement. The final voting results are as follows:


For	Against	Abstain	Broker Non-Votes
21,394,330	1,130,133	48,968	2,415,788


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CASTLE BIOSCIENCES, INC.
	By:	/s/ ~~Frank~~Derek ~~Stokes~~J. Maetzold
		Frank Stokes
		Derek J. Maetzold
		Chief Financial Officer
		President and Chief Executive Officer
Date: May 6, 2026
Date: May 29, 2026

Filing Compare · CASTLE BIOSCIENCES INC